Two Sigma Investments
TCRX icon

Two Sigma Investments’s TScan Therapeutics TCRX Stock Holding History

Two Sigma Investments’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.22M Buy
1,209,009
+557,830
+86% +$596K ﹤0.01% 3108
2025
Q4 		$651K Buy
651,179
+231,775
+55% +$335K ﹤0.01% 3171
2025
Q3 		$763K Buy
419,404
+54,370
+15% +$96.3K ﹤0.01% 2752
2025
Q2 		$529K Buy
365,034
+274,833
+305% +$397K ﹤0.01% 2562
2025
Q1 		$124K Buy
+90,201
New +$195K ﹤0.01% 2934
2024
Q4 		– Sell
-15,745
Closed -$78.4K – 3477
2024
Q3 		$78.4K Buy
+15,745
New +$95K ﹤0.01% 2921
2024
Q2 		– Sell
-37,747
Closed -$300K – 3326
2024
Q1 		$300K Buy
+37,747
New +$237K ﹤0.01% 2561
2021
Q4 		– Sell
-22,817
Closed -$190K – 4877
2021
Q3 		$190K Buy
+22,817
New +$212K ﹤0.01% 3975

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Two Sigma Investments's TCRX Position: Q1 2026 in Review

Two Sigma Investments increased its TScan Therapeutics (TCRX) stake by 86% in Q1 2026, buying an estimated $596K and bringing the position to 1,209,009 shares worth $1.22M. The position accounts for ﹤0.01% of the portfolio, ranked #3108.

Two Sigma Investments first reported a position in TCRX in Q3 2021 and has held it in 8 quarters since. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • Two Sigma Investments held 1,209,009 shares of TScan Therapeutics worth $1.22M as of Q1 2026.
  • Two Sigma Investments bought 557,830 TScan Therapeutics shares in Q1 2026, an estimated $596K.
  • TScan Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #3108 holding.
  • Two Sigma Investments first reported a position in TScan Therapeutics in Q3 2021 and has held it in 8 quarters since.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.